Skip to content
Home
About Us
Why LinKinVax ?
Science
Leadership Team
Partnering & featured deal
Company Responsability
Research & development
Science
Our products
Linkinvax pipeline
Medias
News
Press releases
SUBSCRIBE TO UPDATE
Investors
A unique project
SUBSCRIBE TO UPDATE
Join us (fr)
Contact Us
Menu
Home
About Us
Why LinKinVax ?
Science
Leadership Team
Partnering & featured deal
Company Responsability
Research & development
Science
Our products
Linkinvax pipeline
Medias
News
Press releases
SUBSCRIBE TO UPDATE
Investors
A unique project
SUBSCRIBE TO UPDATE
Join us (fr)
Contact Us
Home
About Us
Why LinKinVax ?
Science
Leadership Team
Partnering & featured deal
Company Responsability
Research & development
Science
Our products
Linkinvax pipeline
Medias
News
Press releases
SUBSCRIBE TO UPDATE
Investors
A unique project
SUBSCRIBE TO UPDATE
Join us (fr)
Contact Us
Menu
Home
About Us
Why LinKinVax ?
Science
Leadership Team
Partnering & featured deal
Company Responsability
Research & development
Science
Our products
Linkinvax pipeline
Medias
News
Press releases
SUBSCRIBE TO UPDATE
Investors
A unique project
SUBSCRIBE TO UPDATE
Join us (fr)
Contact Us
Press releases
LinKinVax has the trust of world-class partners and investors.
download Our press file
Our last
Press releases
LinKinVax and Gustave Roussy announced first patient dosedin Phase I/IIa clinical study on HPV.DCVax in HPV-positiveoropharyngeal cancer
Voir le communiqué
LinKinVax et Gustave Roussy annoncent un premier patienttraité dans l’essai clinique HPV.DCVax de phase I/IIa dans lecancer oropharyngé HPV-positif
Voir le communiqué
LinKinVax completes first batch production of “pancov”,its next generation multi-variant vaccine against covid and other coronaviruses
Voir le communiqué
LinKinVax finalise la production du premier lot d’un vaccin de nouvelle génération, contre la covid et les virus de la même famille.
Voir le communiqué
LinKinVax présente son conseil scientifique avec
la nomination de trois éminents experts en
immunologie et épidémiologie
Voir le communiqué
LinKinVax introduces its Scientific Advisory
Board with the appointment of three leading
experts in immunology and epidemiology
Voir le communiqué
LinKinVax se félicite des résultats intermédiaires de l’essai ANRS VRI06 de phase I d’un nouveau candidat vaccin contre le VIH
Voir le communiqué
LinKinVax welcomes interim results of the ANRS
VRI06 Phase I trial evaluating a novel HIV vaccine
Voir le communiqué
LinKinVax and Gustave Roussy collaborate to conduct a Phase I/IIa HPV.DCVax clinical trial for the treatment of patients with human papillomavirus (HPV) associated oropharyngeal cancer
Voir le communiqué
VIEW MORE
SUBSCRIBE TO UPDATE !
Subscribe
SUBSCRIBE TO UPDATE :
Name
Email
Send